ThioMatrix is specialised on the development of non-invasive drug delivery
systems utilizing its core technology: the Thiomer Technology. Due to its
great potential the efficacy of non-invasively delivered:
- therapeutic peptides
- peptidomimetics
- nucleic
acids such as oligonucleotides, plasmid DNA and siRNA
- class
III drugs according to the biopharmaceutical classification system (BCS)
- drugs
being substrate of efflux pumps such as anticancer drugs
can be tremendously improved.A wide
network of partnerships and collaborations with hospitals, veterinary
institutions, CROs and universities has been established to conduct
preclinical through to clinical development of our delivery products. This
network coupled to our technologies and expertise gives us the edge to
reduce the time to market to develop the optimal delivery systems for your
therapeutic candidates. To learn
more about our drug delivery technologies, please visit the
technology section where you
will also find the results of various
in
vivo studies demonstrating the advantages of our novel drug delivery
products.
